Scripps Research Institute Scientists Develop Powerful New Method for Finding Therapeutic Antibodies As Proof of Principle, Technique Finds Antibody that Mimics Key Hormone for Blood Clotting
LA JOLLA, CA May 23, 2013 Scientists at The Scripps Research Institute (TSRI) have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are already used in many of the world's best-selling medicines, diagnostics and laboratory reagents. The newly reported technique should greatly speed the process of discovering such products.
For the first time, we have a selection method whose power matches the vast diversity of the antibody repertoire, said Richard A. Lerner, the Lita Annenberg Hazen Professor of Immunochemistry at TSRI, member of the Department of Molecular Biology, and senior investigator for the new study, which appears in this week's issue of the Cell Press journal Chemistry and Biology.
As a demonstration of the potential of the new method, Lerner's team used it for the rapid discovery of an antibody that potently mimics thrombopoietin (TPO), a hormone that controls the production of clot-making platelets in blood.
The time from selection of the target through discovery of the antibody and completion of initial animal tests totaled only about five months, said Hongkai Zhang, a research associate in the Lerner laboratory who was first author of the study.
The antibody already has been licensed to a pharmaceutical company for further development.
Fast Selection
Antibodies are large, Y-shaped proteins produced by immune cells called B-cells in humans and many other animals. To cope with diverse and ever-changing threats from microorganisms, B-cells are able to rearrange and mutate a small set of their genes, so that collectively they can produce billions of distinct antibodies.
About two decades ago, Lerner's laboratory developed some of the first techniques for using B-cell gene-mixing to generate very large libraries of antibodies and swiftly determine which of these can bind to a desired target. Since then, Lerner and his colleagues have used these techniques to discover a number of therapeutic antibodies, including the anti-inflammatory antibody Humira , now one of the world's top-selling drugs.
In a major innovation reported last year, Lerner, Zhang and their colleagues developed a basic method for selecting antibodies that not only bind to a given target, such as a cell-surface receptor, but also have a desired biological function such as activating the receptor on mammalian cells. The researchers demonstrated the method by using it to find a potent antibody mimic, or agonist, of erythropoietin (EPO), a hormone that stimulates the production of red blood cells.
But this selection method has one drawback: it determines an antibody's ability to activate a desired biological pathway in a cell by measuring the resulting proliferation of that cell a slow and only narrowly applicable indicator.
We can use this cell-growth test to select for a lot of things including the discovery of antibodies with potential medical uses but Dr. Lerner and I wanted a more direct and generally applicable way of selecting for antibody function, Zhang said.
Two Million Test Cells Per Hour
The new method uses a sensitive reporter system in test cells, which gives off a fluorescent light signal as soon as an antibody succeeds in activating a receptor, or, in principle, any other targeted signaling pathway. The system also is set up so that each test cell produces a unique antibody, whose effect is confined to that cell. Each cell represents a separate assay, said Zhang.
With automation technology that can maintain millions of these cultured test cells, infect them with viral vectors that deliver antibody genes, and then detect the cells that fluoresce, the technique is capable of screening two million test cells per hour.
In the new study, the team proved the value of the new technique by using it to discover a potent agonist of TPO, a hormone that is essential for the proper clotting of blood in wound healing. TPO agonists can treat conditions involving a scarcity of blood platelets, for example as a result of cancer chemotherapy. However, drugs that structurally resemble the TPO hormone can be problematic; about 12 years ago a lab-grown, recombinant version of TPO failed in clinical trials when it was found to induce a deleterious anti-TPO antibody response. This left some patients with less TPO and a lowered platelet count the opposite of the intended treatment effect. Since then, other TPO agonists have been developed without this problem. But there's a real need for more TPO agonists that don't look like natural TPO, said Lerner.
The most powerful TPO agonist described in the study, antibody 3D9, performed much better in cell-culture tests that is, required a much smaller amount to activate the TPO receptor on test cells than TPO itself. At least part of the antibody's potency derives from its greater size and stability compared to a small molecule like TPO, which allows it to stay functional for a longer time.
The mouse TPO receptor is almost identical to human TPO receptor, so Zhang was able to test his antibody agonist in mice. A single, modest dose of 3D9 tripled platelet counts in mice over eight days a much more potent effect than that reported for recombinant TPO. This antibody is what I call a super-agonist, because it's more powerful than the authentic TPO agonist, said Lerner. It also looks superior to the other commercial TPO agonists, based on their reported potencies.
Lerner, Zhang and their colleagues are currently using the new selection method to find other useful antibodies for a variety of applications. One su
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
04/06/2026
Sony Electronics is introducing the SRG-AS10, a 4K 60p-compatible PTZ auto-frami...
04/06/2026
This recent grad from Spring, TX, led creative-video output for the Aggies' men's basketball team last season and has been producing video and creating ...
04/06/2026
For the first time at a women's golf major, every player in the field will r...
04/06/2026
Three Panasonic PT-RQ45 40,000-lumen 3-Chip DLP projectors made their first live...
04/06/2026
Bitmovin and Akamai have announced a collaboration with NRJ Group, a French mult...
04/06/2026
Telestream will exhibit at InfoComm 2026 (Booth N7952), demonstrating media work...
04/06/2026
Sony has announced the development of RIALTO 65, a 65mm format image sensor block for the VENICE 2 digital cinema camera, targeting release in the first half of...
04/06/2026
KOKUSAI DENKI Electric America will exhibit at InfoComm 2026 (Booth N8025, June ...
04/06/2026
Bell Media's TSN and RDS are the exclusive Canadian broadcasters of FIFA Wor...
04/06/2026
The Challenge: Receiving Heavy Media Files From Road Games Quickly and ReliablyT...
04/06/2026
MASV, a managed file transfer platform used in broadcast and live sports product...
04/06/2026
NESN has announced the appointment of Fahad Haider as Vice President of Operations and Engineering. Haider returns to NESN, where he previously served as Vice P...
04/06/2026
David J. Halberstam, who spent almost 50 years in sports as a broadcaster and an executive, died June 2 after a years-long battle with brain cancer.
Over his l...
04/06/2026
Although collegiate production programs are tasked with delivering high-quality ...
04/06/2026
California studio, two production trucks, global distribution system are combine...
04/06/2026
New global program empowers and supports storytellers through scriptwriting course and access to industry experts
TikTok and Sundance Institute today announce...
04/06/2026
Steinberg DAWs now boast in-depth Tonalic integration
Celemony's innovative virtual session musician plug-in has just received an update that brings ARA...
04/06/2026
Get Hands-On With Over 20 Mic Brands
GearExpo UK is fast approaching, and if you've been looking for a chance to check out some new mics, then you'r...
04/06/2026
Combos feature new Amplifier Intelligence engine
Positive Grid's latest release sees the company introduce two new combo amplifiers that promise to offe...
04/06/2026
Is Your Job Making You Work this June?
4 June, 2026
Media releases
SBS Launches the World Cup Watchers' Rights Association to Stand Up For Australians&...
04/06/2026
Statement regarding unauthorised use of SBS logos on third party social content
4 June, 2026
Media releases
SBS has become aware of social media posts in c...
04/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/06/2026
Bitmovin, a leading provider of video streaming infrastructure, and Akamai, the cybersecurity and cloud computing company that powers and protects business onli...
04/06/2026
American Underground (AU), the Startup Hub of the South and a community of mor...
04/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/06/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
04/06/2026
NVIDIA and Microsoft Reinvent Windows PCs for the Age of Personal AI
Brie Clayton June 3, 2026
0 Comments
RTX Spark - a 1-Petaflop Superchip, the Full...
04/06/2026
Inside the Peaky Blinders: The Immortal Man Grade
Brie Clayton June 3, 2026
0 Comments
Simone Grattarola discusses shaping the look in DaVinci Resolve...
04/06/2026
Cine Gear Expo Announces 2026 Awards of Excellence Recipients
Brie Clayton June 3, 2026
0 Comments
Ed Lachman ASC, Caleb Deschanel ASC, and M. David M...
04/06/2026
St. Vincents Live with Orchestra Tour to Feature Berklee Alum Ruby Plume Berklee alumni St. Vincent and Ruby Plume will appear on the same bill across seven d...
04/06/2026
Back to All News
All the Truth in My Lies Coming to Netflix on August 28
Entertainment
04 June 2026
GlobalSpain
Link copied to clipboard
Download the imag...
04/06/2026
Back to All News
Larry Tanz, VP of Content, EMEA, Delivers a Keynote Speech at ...
04/06/2026
Back to All News
Turn Your Living Room into a Stadium With the New FIFA World ...
04/06/2026
Keeping conversations real on LinkedIn Published on Jun 4, 2026 Categories: Product News
LinkedIn Corporate Communications
Share
LinkedIn
Facebook ...
04/06/2026
BackStory follows four Irish young people as they travel back to their parents' homelands
Modern Irish identity is enriched by cultures and influences from...
04/06/2026
June's forecast with GeForce NOW: 100% chance of gaming.
GeForce NOW is lining up new adventures for the month, from big-name blockbusters to quirky indies...
03/06/2026
SES and Viva, Mexico's ultra low-cost airline, have launched multi-orbit satellite inflight connectivity on Viva's Airbus aircraft. A total of 60 A320s ...
03/06/2026
The College Football Playoff, ESPN, and TNT Sports have announced kick times and...
03/06/2026
RED Digital Cinema will exhibit at Cine Gear Expo 2026 (Booth 33, June 5-6, Universal Studios Lot), hosting three panels and hands-on product demonstrations.
P...
03/06/2026
Roku has announced the Soccer Zone, a dedicated hub for FIFA World Cup 2026 content available across the United States, Canada, Mexico, Brazil, Colombia, Argent...
Scripps Research Institute Scientists Develop Powerful New Method for Finding Therapeutic Antibodies As Proof of Principle, Technique Finds Antibody that Mimics Key Hormone for Blood Clotting
